Screener
Allogene Therapeutics ALLO Pre-Tax Income
Discontinued — last reported Q4 '25
Pre-Tax Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The source filing: Allogene Therapeutics’s 10-K, filed March 12, 2026.
- Filed
- Mar 12, 2026, 4:11 PM EDT
- Fiscal year
- FY2025
- Accession
- 0001628280-26-017242
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Interest expense | (1,075) | (181) |
| Other income (expense), net | 215 | (3,920) |
| Total other income (expense), net | 18,429 | 16,052 |
| Loss before income taxes | (190,886) | (257,147) |
| Income tax expense | — | (443) |
| Net loss | (190,886) | (257,590) |
| Other comprehensive loss: | ||
| Net unrealized gain on available-for-sale investments | 358 | 866 |
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is Allogene Therapeutics's pre-tax income?
- Allogene Therapeutics (ALLO) reported pre-tax income of -$47.72M in Q4 2025.
- How has Allogene Therapeutics's pre-tax income changed year-over-year?
- Allogene Therapeutics's pre-tax income increased by 25.8% year-over-year, from -$64.29M to -$47.72M.
- What is the long-term trend for Allogene Therapeutics's pre-tax income?
- Over 3 years (2021 to 2025), Allogene Therapeutics's pre-tax income has grown at a -9.4% compound annual growth rate (CAGR), from -$257.01M to -$190.89M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.
Ask your AI about Allogene Therapeutics's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude